title: Concurrent chronic administration of a CCK(B) antagonist can decrease tolerance to the ataxic effects of ethanol.
abstract: The effects of chronic administration of a CCK(B) antagonist, CAM1028, were examined on the development of tolerance to ethanol and the appearance of withdrawal signs. Ethanol was given chronically by liquid diet, and none of the dose schedules of CAM1028 affected the amount of ethanol taken in during the chronic treatment. Brain ethanol concentrations were not altered by the administration of CAM1028.The ataxic effects of ethanol were tested on a rotorod, 3 hours after cessation of the ethanol administration, and the last injections of CAM1028 were given 8 hours before withdrawal from the ethanol treatment. When administered at 0.03, 0.1 or 0.3 mg/kg, CAM1028 decreased the extent of tolerance development. Higher doses, 1 and 3 mg/kg, did not alter the tolerance development. Chronic administration of CAM1028 had a small effect in protecting against the effects of ethanol withdrawal that, in contrast to the effects on the tolerance, was seen only at the highest dose, 10 mg/kg, of CAM1028.
authors.affiliation: Parke-Davis Neuroscience Research Unit, Addenbrookes Hospital Site, Cambridge, UK.
authors.forename: J
authors.initials: J
authors.lastname: Wilson
authors.forename: G N
authors.initials: GN
authors.lastname: Woodruff
authors.forename: H J
authors.initials: HJ
authors.lastname: Little